ParagonDx, a genetics testing firm, is partnering with a Washington state company for testing of patients to see if they are sensitive to the blood thinner warfarin.

ParagonDx technology will enable Iverson Genetic Diagnostics to determine test results within hours rather than days for tests that relied on blood. The ParagonDx test will be based on saliva.

“With this test, Iverson Genetics is making the practical benefits of warfarin testing – improved safety and decreased adverse drug reactions –  reality for patients now,” said ParagonDx Chief Executive Officer Michael Murphy.

Financial terms of the agreement were not disclosed. Iverson is based in Seattle, Wash.

“Doctors need to make dosing decisions about warfarin on the spot,” said Dean Sproles, the chief executive officer and founder of Iverson Genetics. “Our same-day turnaround will bring the benefits of genetic testing to patients immediately. Doctors and clinics have enthusiastically welcomed our warfarin test, and we expect to do at least 5,000 tests per month by July.”